A 35 year old female patient was admitted to the female medicine ward with complaints of bodyache with weakness, pain in knee joint since 2-3 months, difficulty in walking. she had a past history of TB lymphadenopathy.
A 35 year old female patient was admitted to the female medicine ward with complaints of bodyache with weakness, pain in knee joint since 2-3 months, difficulty in walking. she had a past history of TB lymphadenopathy.
SubjectiveChief complaint headaches and blurriness of visi.docxpicklesvalery
Subjective:
Chief complaint: headaches and blurriness of vision on the right side
History of present illness: the patient is 67 years old Caucasian female, she complains of having had headaches for 2 weeks now. The pain is located in the right temporal area. She describes the pain as 8-10/10, sharp, constant, interferes with her sleep, she states that nothing aggravates it, not even the bright lights or high sounds, but she gets a little relief by taking Ibuprofen 800 mg. She stated that she has been having some blurriness in the right eye, while her left eye is fine. She also complains of pain in her jaw and tongue while chewing food. Her appetite has been low, and lost about 5 pounds in the last 2 weeks. She noticed low grade fever as well. She also reported ringing sounds in the right ear. She denies any nausea or vomiting. She denied having similar headaches in the past. The patient denies complaining of nasal or postnasal drainage.
PMH: past medical history is significant for Hypertension, type II diabetes mellitus, asthma, and degenerative arthritis of the knees.
PSH: hysterectomy
Medications: Lisinopril 10 mg PO QD
Metformin 500 mg PO BID.
Proair HFA 2 puffs PRN.
Ibuprofen 800 mg TID
Multivitamins
By comparing the medications that the patient is taking with Beers criteria, they all looked appropriate to be used in elderly patients.
Family Hx:
Father: HTN, diabetes, and stroke.
Mother: HTN, Diabetes, and breast cancer at the age of 72.
Social Hx: the patient never smoked tobacco products.
ETOH: social drinker
Illicit substances: denies ever using illicit drugs.
Allergies: penicillin.
Review of systems:
Constitutional: the patient complains of fever, fatigue, anorexia, and weight loss.
Head: the patient denies complaining dizziness or lightheadedness.
Eyes: blurriness in the right eye.
Ears: the patient reports tinnitus- right ear, but denies complaining of ear pain or ear discharge
Nose: the patient denies any nasal bleeding, discharge or obstruction
Mouth: the patient reports painful chewing, she denies gingival bleeding, having mouth sores, or having dental difficulties
Throat: no sore throat
Cardiovascular: the patient denies complaining of Chest pain, palpitations, or swelling in the legs.
Respiratory: the patient denies any wheezing, shortness of breath or coughing.
Gastrointestinal: the patient denies any nausea, vomiting, GERD, epigastric pain, diarrhea, constipation, having black stools, or blood in stool.
Genitourinary: the patient denies any dysuria, polyuria, or visible hematuria
Musculoskeletal: bilateral knee pain.
Integumentary (Skin): the patient denies having any skin rash or skin discolorations.
Neurological: the patient denies complaining of tingling or numbness in any extremity; there is no history of seizures, stroke, syncope, or memory changes.
Psychiatric: the patient denies complaining of depression, or anxiety, denies complaining of hallucinations.
Endocrine: the pat ...
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
A case study on systemic lupus erythamatosus
1. A Case study on Systemic
lupus erythematosus
09408103
Pharm.D (V year)
Clerkship
20-12-2013
2. CASE STUDY ON SLE
A 45 years female patient was admitted in the hospital on
DECEMBER 16th ,2013.
CHIEF COMPLAINTS:
C/O cough with sputum production for past 8 days.
H/O fever on and off for 5 days.
3. • HISTORY OF PRESENT ILLNESS:
• The patient is a K/C/O systemic lupus erythematosus and was
on treatment for the past 2 years and was on regular follow up.
• She was admitted for fever on and off for the past 5 days .
• She has cough with yellowish sputum for the past 8 days.
• She has an H/O photosensitivity and dental caries.
• Malar rashes
4. But she does not have a H/O throat pain, burning micturition,
joint pain or exacerbation of skin lesions, oral ulcers, chest
pain or headache.
• PAST MEDICAL HISTORY:-
She has burning sensation in eyes, SLE
• PAST MEDICATION HISTORY:
She was given methyl prednisolone (500mg in 5% dextrose)
pulse therapy during her last admission.
5. • PERSONAL HISTORY:
• Insomnia is present
• She is taking mixed diet and there is no loss of appetite.
• Normal bowel and bladder habits
• FAMILY HISTORY:
• Nothing significant
6. • PHYSICAL EXAMINATION:
A. GENERAL EXAMINATION:
Temperature : 101F (↑)
Pulse rate : 80 beats /min
Respiratory rate : 22 breaths / min
Blood pressure : 100/ 80 mmHg
8. • DERMATOLOGICAL EXAMINATION:
• Scalp: Female pattern hair loss and thinning of scalp hair.
Erythematous plaque present in vertex.
• Face: Well defined erythematous plaques are present with
surrounding hyperpigmentation in neck ‘v’, trunk and back.
• Oral cavity: Curdy white plaques are present on the dorsum of
the tongue.
9. • Upper Limbs: Similar lesions are seen on the dorsum of hand
extensor aspect of upper limb.
• Lower Limbs: Well defined erythematous plaques are seen on
the medial aspect of left leg.
• Nails: Onycholysis in the right ring finger. Anonychia in the
left forefinger.
12. TRATMENT
DRUGS DOSE ROA FREQUENCY DURATION
TAB.
WYSOLONE
20mg P/O 1-0-1 2 days
TAB.
HCQ
200mg P/O 0-0-1 2 days
TAB.
NEXPRO
40mg P/O 1-0-1 2 days
TAB.
SHELCAL
500mg P/O 1-0-0 2 days
TAB.
DOLO
650mg P/O 1-0-1 2 days
TAB.
FLUCONAZO
LE
150mg P/O STAT 2 days
13. SOAP NOTES:
• Subjective:
The patient has cough with sputum production for past 10 days
and H/O fever on and off for 3 days.
• Objective:
DERMATOLOGICAL EXAMINATION:
• Scalp: Female pattern hair loss and thinning of scalp hair.
Erythematous plaque present in vertex.
• Face: Well defined erythematous plaques are present with
surrounding hyperpigmentation in neck ‘v’, trunk and back.
14. • Oral cavity: Curdy white plaques are present on the dorsum of
the tongue.
• Upper Limbs: Similar lesions are seen on the dorsum of hand
extensor aspect of upper limb.
• Lower Limbs: Well defined erythematous plaques are seen on
the medial aspect of left leg.
• Nails: Onycholysis in the right ring finger. Anonychia in the
left forefinger.
15. • Vital signs were found to be normal in this patient. But the
laboratory investigations showed variations in certain
parameters like:
• Albumin: 7.2 g/dl (↑)
• Globulin: 3.7 g/dl (↑)
Assessment:
The patient is diagnosed with ‘Systemic lupus erythematosus.’
16. Plan of Treatment:
The Patient was treated with Corticosteroids,
hydroxychloroqine, Proton pump inhibitors, calcium
supplements, Antibiotics & NSAIDS.
17. PATIENT COUNSELLING
• Strictly adhere to the drug regimen.
• Avoiding sunlight is the primary change to the lifestyle
• Occupational exposure to silica, pesticides and mercury can
also make the disease worsen.
• Don’t stop any drug when feeling better.
• Report to the physician if you experience any adverse effects.
• Eat a healthy diet. A healthful diet is one that is low in
saturated fat and rich in whole grains, fruits and vegetables.